

# US Cancer Vaccine Market Outlook 2020

<https://marketpublishers.com/r/UECE2921CD2EN.html>

Date: May 2015

Pages: 420

Price: US\$ 2,000.00 (Single User License)

ID: UECE2921CD2EN

## Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Escalating cancer incidences have made the investigators to come forth with therapeutics that could reduce high morbidity and mortality rates. Cancer segment has several products belonging to different categories having different pharmacological efficacy. So, it becomes imperative for investigators to develop products that have both high pharmacological and commercialization potential. Numerous cancer therapeutic is available in market but they have limited pharmacological efficacy and high unmet medical necessities prevails across the globe. Vaccination has been successfully employed to treat various infectious diseases and this idea has been extended to treat different malignancies. In past few decades, various malignancies have increased several folds in US due to which regulatory authorities are willing to accept cancer vaccines as a viable option. After hard work of several decades, investigators have been able to successfully market cancer vaccines in US market.

Cancer vaccines could be divided into to two broad categories of prophylactic (preventive) and therapeutic (treatment) segments. In US, cancer vaccines belong to both of these groups have been marketed in past few decades. Food and Drug Administration (FDA) is taking effective measures to offer better medical care to cancer patients. They are willing to try newer modalities due to which pharmaceutical companies are actively engaged for developing them for different malignancies. Due to this reason cancer vaccines got marketing approval in US and in clinical trials they have generated significant data. Increasing demand and higher acceptance rates among patients are expected to increase their sales due to which pharmaceutical companies are actively competing to generate more revenues from this segment. In future, number of clinical trials is expected to increase to develop cancer vaccines for different malignancies. Some of the products are different stages of clinical trials which are expected to be commercialized in US in coming years.

Cancer vaccines for malignancies developed as a result of infectious agents has gained acceptance in past few years and success of HPV vaccines encourages pharmaceutical companies to invest significantly in this segment. Moreover, FDA has already approved hepatitis B vaccine for hepatic carcinoma but cure for hepatitis C remains elusive. This segment may develop a whole new segment of cancer vaccines and time will tell about success of these measures. In future, it may happen that cancer vaccines for various malignancies caused by infectious agents will become easily available in US. Main emphasis is being given on Kaposi's sarcoma which is Human Immunodeficiency Virus (HIV) associated malignancy. Till date no effective treatment for Kaposi's sarcoma is available but by activating patients' immune system with the help of cancer vaccines it could be treated. In recent years, investigators have been able to find putative link between H. pylori and gastric cancer. These indices have less frequency but these cases are increasing and there are no competitive products in US market as a result of which significant opportunity to churn significant revenues exists for pharmaceutical companies.

US is expected to become one of the largest market for cancer vaccines due to amenable regulatory rules for newly developed medicinal products. FDA is known to provide early marketing approval to products if breakthrough is produced at early stages of clinical trials. This will allow the cancer patients use cancer vaccine for their treatment without waiting for long time. Recently, US has agreed to introduce lung cancer vaccine developed in Cuba to be used in clinical trials for checking its safety and efficacy. If this lung cancer vaccine proves its worth in clinical trials performed in US, then it will get marketing approval. Due to increasing cancer incidences, it has become necessary to take such steps which will help the large population base suffering from different malignancies. Hopefully, pharmaceutical companies will try to take introduce their cancer vaccines as soon as possible in US to occupy major market shares due to which more cancer patients will get highly effective cancer vaccines.

US Cancer Vaccine Market Outlook 2020' Report Highlight:

US Cancer Vaccine Market Analysis

Cancer Vaccine with Orphan Status

US Cancer Vaccine Clinical Pipeline by Company, Indication & Phase

US Cancer Vaccine Clinical Pipeline: 187 Vaccines

Clinical Insight of Marketed Cancer Vaccines in US

Marketed Cancer Vaccine in US: 5 Vaccines

FDA Regulations for Clinical Trials of Cancer Vaccines

Clinical Insight of Marketed Cancer Vaccines in US

Bladder Cancer Vaccine - ID Biomedical (PACIS)

Bladder Cancer Vaccine - Organon Teknika (OncoTICE)

Human Papillomavirus Vaccine Quadrivalent - Merck (Gardasil)

Human Papillomavirus Vaccine Recombinant Bivalent - GlaxoSmithKlinee  
(Cervarix)

Prostate Cancer - Dendreon Corporation (Provenge)

## Contents

### **1. INTRODUCTION TO CANCER VACCINE**

### **2. CANCER VACCINE MECHANISM & INNOVATIONS**

- 2.1 Idiotypic Cancer Vaccine Mechanism
- 2.2 Cellular Cancer Vaccines Mechanism
- 2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
- 2.4 Peptide Cancer Vaccine Mechanism
- 2.5 Tumor Host Interaction Cancer Vaccine Mechanism

### **3. ADJUVANTS PLATFORMS FOR CANCER VACCINE DELIVERY**

### **4. US CANCER INCIDENCE & PREVALENCE**

- 4.1 Leading Cancer Incidence
- 4.2 Incidence by State
- 4.3 Incidence by Gender
- 4.4 Incidence by Age Group

### **5. US CANCER VACCINE MARKET ANALYSIS**

- 5.1 Current Market Scenario
- 5.2 Cancer Vaccine Clinical Pipeline Analysis
- 5.3 Pricing & Reimbursement Policy

### **6. CANCER VACCINE WITH ORPHAN STATUS**

### **7. CANCER RESEARCH FUNDING & GRANTS**

### **8. US CANCER VACCINE MARKET DYNAMICS**

- 8.1 Favorable Market Parameters
- 8.2 Market Challenges

### **9. US CANCER VACCINE MARKET FUTURE GROWTH OPPORTUNITIES**

## **10. US CANCER VACCINE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE**

- 10.1 Research
- 10.2 Preclinical
- 10.3 Clinical
- 10.4 Phase-I
- 10.5 Phase-I/II
- 10.6 Phase-II
- 10.7 Phase-II/III
- 10.8 Phase-III
- 10.9 Registered

## **11. CLINICAL INSIGHT OF MARKETED CANCER VACCINES IN US**

- 11.1 Bladder Cancer Vaccine - ID Biomedical (PACIS®)
- 11.2 Bladder Cancer Vaccine - Organon Teknika (OncoTICE)
- 11.3 Human Papillomavirus Vaccine Quadrivalent - Merck (Gardasil®)
- 11.4 Human Papillomavirus Vaccine Recombinant Bivalent - GlaxoSmithKline/MedImmune (Cervarix®)
- 11.5 Prostate Cancer - Dendreon Corporation (Provenge®)

## **12. DISCONTINUED & SUSPENDED CANCER VACCINE IN CLINICAL PIPELINE**

- 12.1 No Development Reported
- 12.2 Discontinued
- 12.3 Suspended

## **13. FDA REGULATIONS FOR CLINICAL TRIALS OF CANCER VACCINES**

- 13.1 Considerations for both Early and Late Phase Clinical Trials
  - 13.1.1 Patient Population
  - 13.1.2 Monitoring the Immune Response
  - 13.1.3 Biomarkers as Evidence of Efficacy
  - 13.1.4 Adjuvants Used To Stimulate Immune Response
  - 13.1.5 Multi-Antigen Vaccines
  - 13.1.6 Disease Progression/Recurrence Immediately or Shortly After the Initial Administration of Cancer Vaccines
  - 13.1.7 Concomitant & Subsequent Therapies

## 13.2 Considerations for Early Phase Clinical Trials

### 13.2.1 Starting Dose & Dosing Schedule

### 13.2.2 Booster & Maintenance Therapy

### 13.2.3 Dose Escalation

### 13.2.4 Single-Arm versus Randomized Phase 2 Trials In Early Development

## 13.3 Considerations for Late Phase Clinical Trials

### 13.3.1 Safety Profile from Early Phase Clinical Trials

### 13.3.2 Endpoints

### 13.3.3 Statistical Issues

### 13.3.4 Control Issues

### 13.3.5 Delayed Vaccine Effect

### 13.3.6 Autologous Vaccine Trials

### 13.3.7 Accelerated Approval Regulations

## 14. COMPETITIVE LANDSCAPE

### 14.1 Aduro BioTech

### 14.2 Advaxis

### 14.3 Antigen Express

### 14.4 Argos Therapeutics

### 14.5 Bavarian Nordic

### 14.6 Celldex Therapeutics

### 14.7 Cosmo Pharmaceuticals

### 14.8 Dendreon Corporation

### 14.9 Galena Biopharma

### 14.10 Generex Biotechnology

### 14.11 Gradalis

### 14.12 GSK

### 14.13 Merck

### 14.14 NewLink Genetics

### 14.15 Oxford BioMedica

## List Of Figures

### LIST OF FIGURES

Figure 1-1: Categorization & Function of Cancer Vaccines

Figure 2-1: Classification of Different Types of Cancer vaccines

Figure 5-1: US Cancer Vaccine Market (US\$ Billion), 2014-2020

Figure 5-2: US Share in Global Cancer Vaccines Market (%), 2014 & 2020

Figure 5-3: US Vaccine Market by Therapeutic & Prophylactic Vaccines, 2014 & 2020

Figure 5-4: US Prophylactic Cancer Vaccines Market, (US\$ Billion), 2014-2020

Figure 5-5: US Therapeutic Cancer Vaccines Market, (US\$ Billion), 2014-2020

Figure 5-6: US Cancer Vaccine Pipeline by Phase (%), 2015

Figure 5-7: US Cancer Vaccine Pipeline by Phase (Number), 2015

Figure 5-8: No Development Reported US Cancer Vaccine Pipeline by Phase (%), 2015

Figure 5-9: No Development Reported US Cancer Vaccine Pipeline by Phase (Number), 2015

Figure 5-10: Discontinued US Cancer Vaccine Pipeline by Phase (%), 2015

Figure 5-11: Discontinued US Cancer Vaccine Pipeline by Phase (Number), 2015

Figure 5-12: Suspended US Cancer Vaccine Pipeline by Phase (%), 2015

Figure 5-13: Suspended US Cancer Vaccine Pipeline by Phase (Number), 2015

Figure 14-1: Advaxis Clinical Pipeline

Figure 14-2: Argos Therapeutics Clinical Pipeline

Figure 14-3: Cosmo Pharmaceuticals Clinical Pipeline

Figure 14-4: Gradalis Clinical Pipeline

Figure 14-5: NewLink Genetics Clinical Pipeline

## List Of Tables

### LIST OF TABLES

Table 4-1: Estimated Number of New Cases for Selected Cancers by State, 2015

Table 4-2: Estimated Number of Deaths for Selected Cancers by State, 2015

Table 4-3: Estimated Number of New Cancer Cases and Deaths by Gender, 2015

Table 4-4: Estimated New Cancer Cases by Age (Years), 2015

Table 4-5: Estimated Cancer Deaths by Age (Years), 2015

Table 6-1: US Orphan Designated Cancer Vaccines

Table 7-1: Spending on Cancer Research (US\$ Million), 2010-2012

Table 7-2: Grants for Cancer Research (US\$), 2013

Table 7-3: Grants for Cancer Research by States (US\$), 2013

Table 7-4: Cancer Funding by Area of Research (US\$)

Table 14-1: Aduro BioTech Cancer Vaccine Pipeline

Table 14-2: Aduro BioTech Cancer Immunotherapies

Table 14-3: Antigen Express Cancer Vaccine Pipeline

Table 14-4: Bavarian Nordic Cancer Vaccine Pipeline

Table 14-5: Celldex Therapeutics Cancer Vaccine Pipeline

Table 14-6: Dendreon Corporation Cancer Vaccine Pipeline

Table 14-7: Galena Biopharma Cancer Vaccine Pipeline

Table 14-8: GSK Cancer Vaccine Pipeline

Table 14-9: Merck Cancer Vaccine Pipeline

Table 14-10: Oxford BioMedica Cancer Vaccine Pipeline

### COMPANIES

Aduro BioTech, Advaxis, Antigen Express, Argos Therapeutics, Bavarian Nordic, Celldex Therapeutics, Cosmo Pharmaceuticals, Dendreon Corporation, Galena Biopharma, Generex Biotechnology, Gradalis, GSK, Merck, NewLink Genetics, Oxford BioMedica



## I would like to order

Product name: US Cancer Vaccine Market Outlook 2020

Product link: <https://marketpublishers.com/r/UECE2921CD2EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UECE2921CD2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970